ClinicalTrials.gg
CompletedNCT04753437Updated Aug 31, 2023Results posted

A Study of Vonoprazan in Adults With Helicobacter Pylori

A Phase 1 interventional study of Clarithromycin and Amoxicillin in Helicobacter Pylori, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Helicobacter Pylori (H Pylori) is a bug found in the digestive system. It can cause soreness and redness in the stomach (gastritis). It can also cause ulcers in the stomach and other parts of the digestive system. Vonoprazan is a medicine to treat people with H Pylori. It is taken together with other medicines to fight infections caused by H Pylori.

The main aim of this study is to learn if vonoprazan changes how the other medicines are processed by the body. It will be compared with another medicine called esomeprazole. Other aims are to check for side effects from the study medicines.

At the first visit, the study doctor will check who can take part. Participants who take part will be picked for 1 of 2 treatments by chance.

  • Vonoprazan taken with bismuth, clarithromycin, and amoxicillin
  • Esomeprazole taken with bismuth, clarithromycin, and amoxicillin

Both treatments will last for 14 days. Participants will stay in the clinic throughout their treatment.

After treatment, the clinic staff will telephone the participants 2 days later for a check-up. The participants will visit the clinic 4 weeks later for a final check-up.

Read the detailed description

This is a study in healthy participants with Helicobacter pylori (HP positive) to evaluate the safety, tolerability and PK of a quadruple therapy with bismuth, clarithromycin, amoxicillin, and vonoprazan versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and esomeprazole.

The treatment phase consists of quadruple therapy twice daily (BID) with bismuth potassium citrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and vonoprazan (20 mg) (Group B) or quadruple therapy BID with bismuth potassium citrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and esomeprazole (20 mg) (Group A) from Days 1 to 14. Participants will be discharged on Day 15 after all procedures have been performed.

This single-center will be conducted in China. Participants will remain confined to the study site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and return on Day 42 for a follow-up assessment.

02

Conditions studied

  • Helicobacter Pylori

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. HP positive participants.
  2. Weighs at least 50 kilogram (kg) and has a between greater than (>) 18 and less than equal to (\<=) 30 kilogram per square meter (kg/m\^2), inclusive, at screening and Day -1 (check-in).
  3. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1) until the Follow-up call on Day 17.

Exclusion criteria

Exclusion Criteria:

  1. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1).
  2. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular consumption of 21 units or more units per week) at any time prior to the Screening Visit or is unwilling to agree to abstain from alcohol and drugs throughout the study (up to Day 17).
  3. Has history of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison syndrome, or has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs.
  4. Has undergone therapeutic upper gastrointestinal endoscopic therapy (example, endoscopic hemostasis or excision including ) within 30 days prior to Screening.
  5. Has undergone major surgical procedures within the past 1 month or are scheduled to undergo surgical procedures that may affect gastric acid secretion (example, abdominal surgery, vagotomy, or craniotomy).
  6. Has a history of cancer, except basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has been in remission for at least 5 years prior to Day 1.
  7. Has a positive test result for surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody/antigen at Screening.
  8. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to Check-in. Cotinine test is positive at Screening or Check-in.
  9. Has poor peripheral venous access.
  10. Has donated or lost 450 milliliter (mL) or more of his blood volume (including plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day 1.
  11. Has abnormal Screening or Check-in laboratory values that suggest a underlying disease or subject with the following laboratory abnormalities: (ALT), aspartate aminotransferase (AST) or total > the (ULN).
  12. Has reduced renal function assessed by having an estimated \<90 milliliter per min per 1.73 square meter (mL/min/1.73 m\^2) (as estimated by Chronic Kidney Disease-Epidemology Collaboration) at Screening or Check-in.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Clarithromycin + Amoxicillin + Bismuth + Vonoprazan

    Clarithromycin 500 milligram (mg), tablets, orally, BID, along with amoxicillin 1000 mg, capsules, orally, BID, bismuth potassium citrate 600 mg, capsules, orally, BID, and vonoprazan 20 mg, tablets, orally, BID on Days 1 to 14.

    Drug: Clarithromycin · Drug: Amoxicillin · Drug: Bismuth potassium citrate · Drug: Vonoprazan

  • Active comparator
    Clarithromycin + Amoxicillin + Bismuth + Esomeprazole

    Clarithromycin 500 mg, tablets, orally, BID, along with amoxicillin 1000 mg, capsules, orally, BID, bismuth potassium citrate 600 mg, capsules, orally, BID, and esomeprazole 20 mg, tablets, orally, BID on Days 1 to 14.

    Drug: Clarithromycin · Drug: Amoxicillin · Drug: Bismuth potassium citrate · Drug: Esomeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Bismuth

    Time frame: Day 14: 0 to 12 hours after the morning dose

  2. AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval τ for Bismuth

    Time frame: Day 14: 0 to 12 hours after the morning dose

  3. Aeτ: Total Amount of Bismuth Excreted in Urine During a Dosing Interval τ for Bismuth

    Time frame: Day 14: 0 to 12 hours after the morning dose

Secondary outcomes

  1. Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug.

    Time frame: From the first dose of study drug up to Day 17

  2. Percentage of Participants Who Discontinued Study Drug Due to a Treatment-Emergent Adverse Event (TEAE)

    Time frame: From the first dose of study drug up to Day 17

07

Results

Posted Aug 31, 2023

Participant flow

Participants took part in the study at 1 investigative site in China from 06 April 2021 to 05 November 2021.

Participant flow — Overall Study
MilestoneClarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + Esomeprazole
Started2222
Completed2017
Not completed25
Withdrew: Pretreatment event/adverse event01
Withdrew: Liver function test abnormalities24

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for Bismuth
Time frame:
Day 14: 0 to 12 hours after the morning dose
Reported as:
Geometric least squares mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Bismuth
nanogram per milliliter (ng/mL)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + Esomeprazole
Cmax: Maximum Observed Plasma Concentration for Bismuth42.8 (32.6 to 56.2)32.9 (24.7 to 43.8)
Statistical analysis
  • Clarithromycin + Amoxicillin + Bismuth + Vonoprazan vs Clarithromycin + Amoxicillin + Bismuth + Esomeprazole · Geometric least squares (ls) mean ratio: 1.30 · 90% CI 0.94 to 1.81
PrimaryAUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval τ for Bismuth
Time frame:
Day 14: 0 to 12 hours after the morning dose
Reported as:
Geometric least squares mean · hour*nanogram/milliliter (h*ng/mL)
AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval τ for Bismuth
hour*nanogram/milliliter (h*ng/mL)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + Esomeprazole
AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval τ for Bismuth146 (117 to 183)137 (108 to 173)
Statistical analysis
  • Clarithromycin + Amoxicillin + Bismuth + Vonoprazan vs Clarithromycin + Amoxicillin + Bismuth + Esomeprazole · Geometric ls mean ratio: 1.07 · 90% CI 0.82 to 1.40
PrimaryAeτ: Total Amount of Bismuth Excreted in Urine During a Dosing Interval τ for Bismuth
Time frame:
Day 14: 0 to 12 hours after the morning dose
Reported as:
Mean · micrograms (μg)
Aeτ: Total Amount of Bismuth Excreted in Urine During a Dosing Interval τ for Bismuth
micrograms (μg)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + Esomeprazole
Aeτ: Total Amount of Bismuth Excreted in Urine During a Dosing Interval τ for Bismuth1026 ± 546.01037 ± 562.5
SecondaryPercentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug.

Time frame:
From the first dose of study drug up to Day 17
Reported as:
Number · percentage of participants
Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE)
percentage of participantsClarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + Esomeprazole
Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE)95.595.5
SecondaryPercentage of Participants Who Discontinued Study Drug Due to a Treatment-Emergent Adverse Event (TEAE)
Time frame:
From the first dose of study drug up to Day 17
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Study Drug Due to a Treatment-Emergent Adverse Event (TEAE)
percentage of participantsClarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + Esomeprazole
Percentage of Participants Who Discontinued Study Drug Due to a Treatment-Emergent Adverse Event (TEAE)9.122.7

Adverse events

Collected over From the first dose of study drug up to Day 17. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clarithromycin + Amoxicillin + Bismuth + Vonoprazan0/22 (0%)0/22 (0%)21/22 (95.5%)
Clarithromycin + Amoxicillin + Bismuth + Esomeprazole0/22 (0%)0/22 (0%)21/22 (95.5%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventClarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + Esomeprazole
DysgeusiaNervous system disorders15/2218/22
Alanine aminotransferase increasedInvestigations9/228/22
Aspartate aminotransferase increasedInvestigations9/227/22
NauseaGastrointestinal disorders1/225/22
HyponatraemiaMetabolism and nutrition disorders3/224/22
Alpha hydroxybutyrate dehydrogenase increasedInvestigations1/223/22
Amylase increasedInvestigations1/223/22
Faeces discolouredGastrointestinal disorders3/221/22
HungerGeneral disorders1/223/22
PruritusSkin and subcutaneous tissue disorders0/223/22

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + EsomeprazoleTotal
Mean34.5 ± 9.6031.6 ± 9.5933.1 ± 9.60
Sex: Female, Male
Sex: Female, Male(Participants)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + EsomeprazoleTotal
Female8917
Male141327
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + EsomeprazoleTotal
Hispanic or Latino000
Not Hispanic or Latino222244
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + EsomeprazoleTotal
American Indian or Alaska Native000
Asian222244
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + EsomeprazoleTotal
China222244
Height
Height(cm)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + EsomeprazoleTotal
Mean167.2 ± 6.58165.6 ± 7.17166.4 ± 6.85
Weight
Weight(kg)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + EsomeprazoleTotal
Mean62.8 ± 9.2363.2 ± 8.2363.0 ± 8.64
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Clarithromycin + Amoxicillin + Bismuth + VonoprazanClarithromycin + Amoxicillin + Bismuth + EsomeprazoleTotal
Mean22.4 ± 2.0723.1 ± 3.0922.7 ± 2.63
08

Study locations

1 site
  • West China Hospital, Sichuan University, Phase I Unit
    Chengdu, Sichuan 610041, China
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Sep 2021, 5 months.

Results were first posted in Aug 2023, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2021
First posted
Feb 15, 2021
StartActual
Apr 6, 2021
Primary completionActual
Sep 27, 2021
CompletionActual
Nov 5, 2021
Results first posted
Aug 31, 2023
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04753437
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Apr 6, 2021
Primary completion
Sep 27, 2021
Completion
Nov 5, 2021
Results posted
Aug 31, 2023
Last update
Aug 31, 2023

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion